Usage Instructions:
Step 1: File the nail Before the first application, file as deeply as possible the affected parts of the nail including the surface, using one of the files provided in the package. ATTENTION: Healthy nails should never be filed with the file used for the diseased nails, it may spread the infection. To prevent spreading the infection, avoid having someone else use the files from your package. | |
Step 2: Clean the nail Use one of the cleansing wipes provided (or nail removers) to clean the surface of the nail. Repeat steps 1 and 2 for each affected nail. | |
Step 3. Extract a little varnish from the bottle Insert one of the reusable spatulas into the varnish bottle. The solution should not touch the neck of the container before application. | |
Step 4: Apply the varnish Apply the varnish uniformly over the entire surface of the nail. | |
Step 5: Clean the applicator The spatulas can be reused. However, it is essential to thoroughly clean after each treatment, using the same wipe used to clean the nails. Avoid touching the recently treated nails with the wipe. Close the varnish bottle tightly. Dispose of the wipe carefully as it is flammable. |
Your doctor will likely check on your treatment progress every 3 months or so.
If you accidentally ingest Teva Amorolfina
If you, or anyone else, accidentally ingest the varnish, contact your doctor, pharmacist, or nearest hospital immediatelyor call the Toxicology Information Service, phone 91 562 04 20 indicating the medication and the amount ingested.
If you forget to use Teva Amorolfina
Don't worry if you forget to use the varnish at the right time. When you remember, start using the product again in the same way as before.
If you interrupt treatment with Teva Amorolfina
Do not stop using Teva Amorolfina before your doctor tells you to, as the infection may return.
If you have any other doubts about using this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Fingernail discoloration, nail breakage, or separation of the nail bed.
These reactions may also be related to the onychomycosis itself.
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Burning sensation on the skin.
Unknown Frequency (cannot be estimated from available data)
Systemic allergic reaction (a serious allergic reaction that may be associated with facial swelling, lip, tongue, or throat swelling, difficulty breathing, and/or intense skin rash).
Redness of the skin, itching, urticaria, blisters, skin allergic reaction (contact dermatitis: skin inflammation caused by contact with the medication).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish Medication Use Human Website:www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
This product is flammable! Keep the solution away from fire and flames!
Medicines should not be disposed of through drains or in the trash. Deposit the containers and medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Amorolfina Teva
The active substance is amorolfina. Amorolfina Teva contains 50 mg/ml of the active substance amorolfina (equivalent to 55.74 mg/ml of chlorhydrate of amorolfina), the other components areEudragit RL100 (Copolímero of metacrilato of amonio type A), triacetina, acetate of butilo, acetate of etilo, anhydrous ethanol.
Appearance of the product and content of the container
Amorolfina is a transparent, colorless to pale yellow solution and is available in
2.5 ml, 3 ml and 5 ml;packaged in 1 bottle with or without cleaning wipes, spatulas and/or nail files
Some container sizes may only be commercially marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Teva Pharma S.L.U.
c/ Anabel Segura 11,
Edificio Albatros B 1st floor,
Alcobendas28108 Madrid (Spain)
Responsible for manufacturing
Chanelle Medical Unlimited Company
Dublin Road, Loughrea
H62 FH90
Ireland
Date of the last review of this leaflet:June 2023
“Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es”
You can access detailed and updated information on this medicine by scanning with your mobile phone (smartphone) the QR code included in the packaging. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/74631/P_74631.html
QR + URL
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.